Yahoo Finance report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Why GRML Stock dropped -10.89% Today — RQD Quant Desk Flash
Greenland Mines Ltd. (GRML) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GRML stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Greenland Mines Ltd. (NASDAQ: GRML) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.58 (-10.89% 1D, market cap $70.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GRML ranks #780 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GRML compare to CGTX and CRDF in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GRML carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGTX (Cognition Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CRDF (Cardiff Oncology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, GRML leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GRML?
▼
Per GRML's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907223), Greenland Mines Ltd. generated $0 in revenue, -$10.6M in net income, and -$5.9M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 39 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a GRML Turnaround Squeeze
While GRML currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.60) and Max Pain ($4.81) forces dealer call-delta covering toward $38.85.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why GRML Stock dropped -10.89% Today — RQD Quant Desk Flash
Greenland Mines Ltd. (GRML) dropped -10.89% to $4.58, trading at 5% of its 52-week range ($2.82 – $37). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($2.82 – $37) with RSI-14 at 39 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.58 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Seeking Alpha report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Mining.com report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
OTC Markets report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
-SEC Filing
Nasdaq-listed critical-minerals developer extends trading access to Deutsche Börse's primary electronic marketplaceXetra network connects trading participants across Europe, Hong Kong and the Middle East, broadening Gree
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRML)
- ✓Walkthrough of GRML's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
GRML Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GRML today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GRML. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRML)
1. Head-to-Head Health Care Peer Comparison (GRML vs. CGTX, CRDF, NMRA, CSBR)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Greenland Mines Ltd. (GRML) ranks #780 by composite RQD confidence (32/100, grade E) and #706 by equity capitalization ($70.3M). Within this direct 5-issuer industry benchmark cohort, GRML leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with GRML at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GRML
ACTIVE
Greenland Mines Ltd. | E | 32/100 | — | — | -35.0% | -10.89% | $70.3M | Benchmark Subject |
| CGTX Cognition Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -5.57% | $70.3M | /cgtx-vs-grml → |
| CRDF Cardiff Oncology Inc. | D- | 41/100 | — | — | -35.0% | -2.46% | $70.9M | /crdf-vs-grml → |
| NMRA Neumora Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -5.43% | $73.0M | /nmra-vs-grml → |
| CSBR Champions Oncology Inc. | E | 22/100 | — | 48.0% | -26.9% | 0.00% | $66.9M | /csbr-vs-grml → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001907223In its most recent audited fiscal period (FY2025, filed 2025-12-31), Greenland Mines Ltd. (GRML) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.6M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (-99.9% YoY). On the balance sheet, GRML closed FY2025 with $9.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$10.6M | -$5.9M | -$5.9M | $9.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$6.2M | -$2.9M | -$2.9M | $2.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$707.5K | -$446.9K | -$446.9K | — | — |
3. GRML Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GRML stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Greenland Mines Ltd. (NASDAQ: GRML) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.58 (-10.89% 1D, market cap $70.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GRML ranks #780 in composite RQD confidence.
How does GRML compare to CGTX and CRDF in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GRML carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CGTX (Cognition Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and CRDF (Cardiff Oncology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, GRML leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GRML?
Per GRML's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001907223), Greenland Mines Ltd. generated $0 in revenue, -$10.6M in net income, and -$5.9M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GRML trading relative to its 50-day, 200-day, and 52-week technical levels?
GRML last traded at $4.58 (-10.89% on volume of 1,359,728 shares), positioning the stock -30.61% below its 50-day simple moving average ($6.60) and -66.67% below its 200-day simple moving average ($13.74). Across its 52-week range of $2.82 to $37.00, GRML sits at the 5.1% percentile with a 14-day RSI of 39.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.01 to $5.15).
GRML Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GRML stock moving today?
Why GRML Stock dropped -10.89% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
GRML — Greenland Mines Ltd.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating assigns GRML a score of 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars are:
- Fundamental Cash Engine: 6 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and FCF yield of -8.37%. For a prospective investor, the company is currently destroying capital and not generating free cash flow relative to its market value, which removes the most durable source of intrinsic support.
- Whale 13F Flow: 5 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is low, indicating limited evidence of sustained institutional conviction in the source data.
- Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the lowest pillar score, meaning the signal from insider and congressional activity does not support the thesis.
- Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. Market-level exposure is neutral by beta, but the score indicates weak alignment with the current macro regime.
- Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. The Piotroski reading is weak, and the score reflects forensic caution despite a moderate Altman Z.
Taken together, the pillars point to a stock where the cash engine, insider signal, and forensic quality all score in the weak range. Upside would depend on a reversal in cash generation, which the current data does not show. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in source data, and the 52-week range of $2.82 to $37 illustrates very high volatility relative to the current $4.58 price.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-7.1M | $-10.6M | N/A | $-5.9M | $7.2M | N/A |
| FY 2024 | $0.0M | $-5.5M | $-6.2M | N/A | $-2.9M | $0.1M | N/A |
| FY 2023 | $0.0M | $-0.6M | $-0.7M | N/A | $-0.4M | N/A | N/A |
Per the SEC financials, reported losses widened across the three periods, with net income moving from $-0.7M to $-10.6M and free cash flow from $-0.4M to $-5.9M. Gross, operating, and net margins are each 0% per the market data, consistent with zero reported revenue. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2/9. Debt/Equity is 0.5 per the Roarable RQD rating, while debt in the SEC financials is Not available in source data for each period; the balance-sheet posture therefore rests on cash of $7.2M at FY 2025 against the company's negative cash flows.
Open Questions
- What products, customers, or development programs generate or are expected to generate revenue, given zero reported revenue in each period?
- What are the debt obligations behind the Debt/Equity of 0.5, since debt is not reported in the SEC financials?
- How much of the $59 million raised is already reflected in the FY 2025 cash of $7.2M, and what is the dilution impact on share count?
- Is the $20M buyback funded from existing cash, and how does it reconcile with negative free cash flow of $-5.9M?
- What is the reason for the 52-week range of $2.82 to $37, and what drove the current $4.58 price?
GRML Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Greenland Mines Ltd. (GRML) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Mining.com report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
OTC Markets report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Greenland Mines Ltd. (GRML) market action, institutional positioning, and fundamental catalysts.
GRML Bull vs. Bear Conversation Board — What's Your Call at $4.58?
🔥 Official Bull vs. Bear Debate: Is GRML (E • RQD 32/100) a Buy at $4.58?
Welcome to the GRML (Greenland Mines Ltd.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on GRML — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on GRML, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Greenland Mines Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
GRML cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on GRML, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $4.58 (52-wk range $2.82 - $37.00), any beat on forward guidance forces shorts and underweight funds to chase.